ArticleScientific reports2026
Antioxidant, antimicrobial, and anticholinesterase activities of A. nitida leaf extract mediated silver nanoparticles.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alnus nitida-derived silver nanoparticles (An-AgNPs) were fabricated using the leaf extract of this medicinal plant, selected for its rich phytochemical profile and strong reducing potential, through a green synthesis approach. The synthesized nanoparticles were previously characterized using standard physicochemical techniques, confirming their nanoscale size, stability, and functional groups responsible for reduction and capping. An-AgNPs and leaves extract were evaluated for their antioxidant (DPPH and ABTS), anti-bacterial, anti-cholinesterase (acetylcholinesterase (AChE), butyrylcholinesterase (BChE)), and anti-diabetic (α-amylase and α-glucosidase) potentials. An-AgNPs showed potent DPPH and ABTS scavenging activities with IC50 values of 125 and 115 µg/mL, followed by leaves extract with IC50 values of 930 and 400 µg/mL, respectively. An-AgNPs also exhibited potential inhibitory activities against AChE, BChE, amylase, and glucosidase with IC50 values of 63, 65, 160, and 65 µg/mL, respectively, whereas the leaves extract exhibited IC50 values of 70, 100, 215, and 235 µg/mL, respectively. The micro-titre plate-based assay of An-AgNPs showed excellent antibacterial activity against both gram-positive bacteria, Staphylococcus aureus (93.76%), Bacillus subtilis (88.35%), and gram-negative bacteria, Escherichia coli (87.67%), Pseudomonas aeruginosa (91.65%), Salmonella typhi (92.28%). The findings of the study demonstrate that An-AgNPs possess significant multifunctional bioactivities and highlight their potential for biomedical and pharmaceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.